Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Merck & Co., Inc.MRK · Entity 2807 | Executive VP & President, MRL | May 05, 2026 | May 07, 2026 |
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | Director | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Merck & Co., Inc.
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2029-05-05 | Direct | 19,885 |
Reported balance
After 2026-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-05 · Grant · Acquired 19,885 · Balance 19,885 F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $113.15 · Expires 2036-05-04 | Direct | 58,207 |
Reported balance
After 2026-05-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-05 · Grant · Acquired 58,207 · Balance 58,207 F3: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. |
| Common StockSEC Table I · non-derivative | Direct | 94,431.05 |
Reported balance
Holding disclosure · report date 2026-05-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 94,431.05 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.
F3: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.
RECURSION PHARMACEUTICALS, INC.
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,476,707 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 3,378 · Balance 1,476,707 F1: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Dean Y. Li Revocable Trust | 1,422,048 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,422,048 |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Dean Y. Li 2021 Family Trust | 421,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 421,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2022 Filed Jul 6, 2022 21:51 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-041281 · doc4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 619,020 F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 00:18 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (right to buy) · Derivative | 36,290 | $0.00 Strike: $6.20 | $0.00 |
DisclosureSEC source: 0001209191-22-037640 · doc4.xml · derivative · entry 6 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,290 Underlying: Class A Common Stock · 36,290 shares Expires 2032-06-14 Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 00:18 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 18,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037640 · doc4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 617,611 F1 · shares: Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 14, 2023 or the day prior to the Issuer's 2023 annual meeting of stockholders. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 773 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013279 · form4.xml · derivative · entry 3 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 773 shares Expires 2022-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 381 | $87.65 | $33,394.65 |
DisclosureSEC source: 0001127602-22-013279 · form4.xml · nonDerivative · entry 2 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,457.945 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:50 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 773 | $87.65 | $67,753.45 |
DisclosureSEC source: 0001127602-22-013279 · form4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,838.945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:11 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 75,728 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013527 · form4.xml · derivative · entry 2 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,728 Underlying: Common Stock · 75,728 shares Expires 2032-05-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 1,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013028 · form4.xml · derivative · entry 3 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062 Underlying: Common Stock · 1,061 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. F3 · balance_after: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 523 | $88.69 | $46,384.87 |
DisclosureSEC source: 0001127602-22-013028 · form4.xml · nonDerivative · entry 2 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,065.945 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:21 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 1,061 | $88.69 | $94,100.09 |
DisclosureSEC source: 0001127602-22-013028 · form4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,588.945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 23:21 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 1,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023302 · doc4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 599,466 F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 21:24 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 3,023 | $73.51 | $222,220.73 |
DisclosureSEC source: 0001127602-22-007019 · form4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,462.118 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 01:46 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 659 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002060 · doc4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 597,922 F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:21 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 1,000 | $21.06 | $21,058.00 |
DisclosureSEC source: 0001209191-21-068918 · doc4.xml · nonDerivative · entry 2 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Dean Y. Li 2021 GRAT Disclosed balance after: 1,315,000 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $21.03 to $21.11 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 02:21 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 14,900 | $20.44 | $304,572.39 |
DisclosureSEC source: 0001209191-21-068918 · doc4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Dean Y. Li 2021 GRAT Disclosed balance after: 1,316,000 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.01 to $20.995 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 22:40 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 13,474 | $20.20 | $272,226.00 |
DisclosureSEC source: 0001209191-21-065896 · doc4.xml · nonDerivative · entry 2 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 578,163 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F3 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.00 to $20.26 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| November 19, 2021 Filed Dec 10, 2021 02:17 UTC Amendment | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 13,474 | $20.20 | $272,226.00 |
DisclosureSEC source: 0001209191-21-068911 · doc4a.xml · nonDerivative · entry 2 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Dean Y. Li 2021 GRAT Disclosed balance after: 1,330,900 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F4 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.00 to $20.26 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. F3 · ownership.direct: The Form 4 filed on November 19, 2021 inadvertently attributed the reported transaction to the incorrect holding. The original Form 4 attributed the reported transaction to the reporting person's direct holding, while the reported transaction should have been attributed to the reporting person's indirect holding by the Dean Y. Li 2021 GRAT. Read SEC document |
| November 17, 2021 Filed Nov 19, 2021 22:40 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 5,626 | $20.04 | $112,736.04 |
DisclosureSEC source: 0001209191-21-065896 · doc4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 591,637 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.00 to $20.13 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. Read SEC document |
| November 17, 2021 Filed Dec 10, 2021 02:17 UTC Amendment | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | SaleClass A Common Stock | 5,626 | $20.04 | $112,736.04 |
DisclosureSEC source: 0001209191-21-068911 · doc4a.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Dean Y. Li 2021 GRAT Disclosed balance after: 1,344,374 F1 · kind: Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person. F2 · price: The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.00 to $20.13 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request. F3 · ownership.direct: The Form 4 filed on November 19, 2021 inadvertently attributed the reported transaction to the incorrect holding. The original Form 4 attributed the reported transaction to the reporting person's direct holding, while the reported transaction should have been attributed to the reporting person's indirect holding by the Dean Y. Li 2021 GRAT. Read SEC document |
| October 01, 2021 Filed Oct 6, 2021 00:24 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 543 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-059736 · doc4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 597,263 F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. F1 · price: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 21:00 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 330 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-045552 · doc4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596,720 F1 · shares: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. F1 · price: The shares were issued pursuant to the Issuer's Outside Director Compensation Policy. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 694 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015763 · form4.xml · derivative · entry 4 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 694 shares Expires 2021-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2019, 5/4/2020 and 5/4/2021. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 91,837 | $0.00 Strike: $75.99 | $0.00 |
DisclosureSEC source: 0001127602-21-015763 · form4.xml · derivative · entry 3 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,837 Underlying: Common Stock · 91,837 shares Expires 2031-05-03 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 238 | $75.98 | $18,083.24 |
DisclosureSEC source: 0001127602-21-015763 · form4.xml · nonDerivative · entry 2 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,309.914 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2021 Filed May 6, 2021 20:55 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 694 | $75.98 | $52,730.12 |
DisclosureSEC source: 0001127602-21-015763 · form4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,547.914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2021 Filed May 4, 2021 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015262 · form4.xml · derivative · entry 6 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750 Underlying: Common Stock · 750 shares Expires 2022-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| May 03, 2021 Filed May 4, 2021 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 257 | $74.50 | $19,146.50 |
DisclosureSEC source: 0001127602-21-015262 · form4.xml · nonDerivative · entry 4 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,853.914 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 03, 2021 Filed May 4, 2021 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 750 | $74.50 | $55,875.00 |
DisclosureSEC source: 0001127602-21-015262 · form4.xml · nonDerivative · entry 3 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,110.914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 1,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-015262 · form4.xml · derivative · entry 5 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,060 Underlying: Common Stock · 1,030 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 354 | $74.50 | $26,373.00 |
DisclosureSEC source: 0001127602-21-015262 · form4.xml · nonDerivative · entry 2 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,360.914 Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:57 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 1,030 | $74.50 | $76,735.00 |
DisclosureSEC source: 0001127602-21-015262 · form4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,714.914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionSeries A-1 Preferred Stock · Derivative | 32,685 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028040 · doc4.xml · derivative · entry 15 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Dean Li and Ruth Li Revocable Trust Disclosed balance after: 0 Underlying: Common Stock · 32,685 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. F1 · derivative.exercise_date: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. F1 · derivative.expiration_date: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. F1 · derivative.underlying: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionSeries A Preferred Stock · Derivative | 22,698 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028040 · doc4.xml · derivative · entry 14 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Dean Li and Ruth Li Revocable Trust Disclosed balance after: 0 Underlying: Common Stock · 22,698 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. F1 · derivative.exercise_date: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. F1 · derivative.expiration_date: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. F1 · derivative.underlying: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 27,778 | Not disclosed Strike: $18.00 | Not disclosed |
DisclosureSEC source: 0001209191-21-028040 · doc4.xml · derivative · entry 13 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,778 Underlying: Class A Common Stock · 27,778 shares Expires 2031-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. F4 · derivative.exercise_date: The option becomes exercisable as to 1/3rd of the shares subject to the option on each anniversary of April 15, 2021, subject to the Reporting Person's continuous status as a service provider through each such date. F1 · derivative.underlying: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionStock Option (Right to Buy) · Derivative | 27,778 | Not disclosed Strike: $18.00 | Not disclosed |
DisclosureSEC source: 0001209191-21-028040 · doc4.xml · derivative · entry 12 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,778 shares Expires 2031-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. F4 · derivative.exercise_date: The option becomes exercisable as to 1/3rd of the shares subject to the option on each anniversary of April 15, 2021, subject to the Reporting Person's continuous status as a service provider through each such date. F1 · derivative.underlying: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherClass A Common Stock | 13,889 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028040 · doc4.xml · nonDerivative · entry 11 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596,390 F3 · shares: The shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of common stock of the Issuer, with 1/3rd of the total amount being received on each anniversary of April 16, 2021. F2 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherCommon Stock | 13,889 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028040 · doc4.xml · nonDerivative · entry 10 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · shares: The shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of common stock of the Issuer, with 1/3rd of the total amount being received on each anniversary of April 16, 2021. F2 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherClass A Common Stock | 582,501 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028040 · doc4.xml · nonDerivative · entry 9 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 582,501 F2 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherCommon Stock | 582,501 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028040 · doc4.xml · nonDerivative · entry 8 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherClass A Common Stock | 1,350,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028040 · doc4.xml · nonDerivative · entry 7 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Dean Y. Li 2021 2021 GRAT Disclosed balance after: 1,350,000 F2 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherCommon Stock | 1,350,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028040 · doc4.xml · nonDerivative · entry 6 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Dean Y. Li 2021 2021 GRAT Disclosed balance after: 0 F2 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherClass A Common Stock | 450,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028040 · doc4.xml · nonDerivative · entry 5 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Dean Y. Li 2021 2021 Family Trust Disclosed balance after: 450,000 F2 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherCommon Stock | 450,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028040 · doc4.xml · nonDerivative · entry 4 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Dean Y. Li 2021 2021 Family Trust Disclosed balance after: 0 F2 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherClass A Common Stock | 1,422,048 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028040 · doc4.xml · nonDerivative · entry 3 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Dean Li and Ruth Li Revocable Trust Disclosed balance after: 1,422,048 F2 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | OtherCommon Stock | 1,422,048 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028040 · doc4.xml · nonDerivative · entry 2 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Dean Li and Ruth Li Revocable Trust Disclosed balance after: 0 F2 · price: Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO. Read SEC document |
| April 20, 2021 Filed Apr 23, 2021 00:06 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | ConversionCommon Stock | 55,383 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-028040 · doc4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Dean Li and Ruth Li Revocable Trust Disclosed balance after: 1,422,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Read SEC document |
| April 16, 2021 Filed Apr 19, 2021 23:28 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantCommon Stock | 13,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-027406 · doc4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596,390 F1 · security: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. F2 · shares: The shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of common stock of the Issuer, with 1/3rd of the total amount being received on each anniversary of April 16, 2021. Read SEC document |
| April 15, 2021 Filed Apr 19, 2021 23:28 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantStock Option (Right to Buy) · Derivative | 27,778 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-21-027406 · doc4.xml · derivative · entry 5 Li Dean Y · CIK 0001837016 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,778 Underlying: Common Stock · 27,778 shares Expires 2031-04-14 F3 · derivative.exercise_date: The option becomes exercisable as to 1/3rd of the shares subject to the option on each anniversary of April 15, 2021, subject to the Reporting Person's continuous status as a service provider through each such date. F1 · derivative.underlying: Immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock, each share of Common Stock shall be reclassified into one share of Class A Common Stock. Each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock shall automatically convert into Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Each share of Series C Preferred Stock shall automatically convert into Common Stock on a 1.1869358:1 basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and has no expiration date. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 17:00 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 3,485 | $72.62 | $253,080.70 |
DisclosureSEC source: 0001127602-21-008587 · form4.xml · nonDerivative · entry 1 Li Dean Y · CIK 0001837016 · Executive VP & President, MRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,655.093 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/18. Performance shares were paid out at 166 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2020. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.